SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (4211)2/16/2000 2:03:00 PM
From: Biomaven  Read Replies (1) of 10280
 
More potent, faster onset and safer.

Maybe even more than this. Take a look at the abstracts from

apnet.com

The following one is particularly interesting. If they can get a "stuffiness" label, it will certainly distinguish them from the other antihistamines:

Abstract No.: 1122

Decongestant Effects of Desloratadine in Patients With Seasonal Allergic
Rhinitis

A Nayak , R Lorber, LM Salmun
Peoria School of Medicine, University of Illinois, Peoria, IL
Schering-Plough Research Institute, Kenilworth, NJ

Subject: 08 Rhinitis Therapy
Keywords: 186 rhinitis therapy

Nasal congestion/stuffiness is a chronic symptom in patients with seasonal
allergic rhinitis (SAR). Currently available antihistamines are not
effective in treating nasal congestion/stuffiness. Desloratadine (DL) is a
selective histamine H1-receptor antagonist with additional antiallergic and
anti-inflammatory effects. Once-a-day dosing relieves nasal and non-nasal
signs and symptoms of SAR and improves health-related quality of life. The
effects of DL on nasal congestion/stuffiness are described by using data
pooled from randomized, parallel-group, double-blind, placebo-controlled
studies of DL in patients with SAR.

Patients (12-75 years; pooled n=659-662/group) with a 2-year history of SAR
and moderate-to-severe symptoms present at the time of enrollment received
DL (5 mg or 7.5 mg) or placebo PO once a day for 14 days. The severity
(0=none, 1=mild, 2=moderate, 3=severe) of congestion/stuffiness was assessed
by patients for the study duration. The 14-day average change in symptom
severity score from baseline was assessed. The mean symptom severity score
for nasal congestion/stuffiness was 2.4 in each treatment group at baseline,
indicating patients had moderate-to-severe nasal congestion before receiving
treatment. DL significantly decreased nasal congestion/stuffiness (P=0.02
and 0.01 for 5 mg and 7.5 mg, respectively, of DL vs placebo) as well as
total symptom severity.

These data indicate that desloratadine, unlike what is generally observed in
other anithistamines, has the added benefit of providing significant relief
from allergic symptoms such as nasal congestion/stuffiness in patients with
SAR.


BTW, there are also 2 levalbuterol abstracts, neither particularly
remarkable.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext